Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed

Inclusion Criteria: * Understand and voluntarily sign an informed consent form. * Age \> 18 years at the time of signing the informed consent form. * Able to adhere to the study visit schedule and other protocol requirements according with investigator criteria. * Diagnosis of symptomatic primary systemic amyloidosis based on tissue Congo red positive staining as well as positive immunohistochemical staining for light chains or presence of a monoclonal protein in serum and/or urine or clonal bone marrow plasma cells * Previously untreated disease * Patients should not candidates for up-front high-dose therapy/stem cell transplantation * Serologically measurable disease defined as follows: Evidence of a monoclonal light chain in serum and urine by immunofixation Raise of the level of circulating free light chains above the ordinary limits and an abnormal relationship kappa/lambda. * Performance status ECOG ≤ 2 (see Annex 3). * Laboratory tests results within these ranges: Absolute neutrophil count ≥ 1 x 10 9/ L. Platelet count ≥ 100 x 10 9/ L Serum creatinine less than 3.0 mg/dL Serum bilirubin less than 3.0 mg/dL \- Females of childbearing potential (FCBP) must agree to: Know the teratogenic risks of the study drug Commit to use contraceptives during the 4 weeks before the start of this study drug treatment, during the treatment and also 4 weeks after it, even amenorrheic cases. All of it applies always except women committed to maintain sexual abstinence confirming it …